The world’s first malaria vaccine has been given the green light by drug regulators in Europe.
Malaria killed more than half a million people in 2013 and most of those who died were children living in Sub-Saharan Africa.
British drugmaker GlaxoSmithKline has been trying to develop a malaria vaccine for 30 years. The vaccine is called Mosquirix, and it has shown effectiveness at fending off the mosquito-born disease in trials. It has shown effectiveness at fending off the mosquito-born disease in trials, but there are still big concerns about how well it will actually work.
Carla Botting of the Malaria Vaccine Initiative joins Here & Now‘s Meghna Chakrabarti to talk about the significance of the vaccine and its early-trial results.
Guest
- Carla Botting, director of product development and access for the PATH Malaria Vaccine Initiative.
Copyright 2021 NPR. To see more, visit https://www.npr.org.